Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues

Apr 23 2007

• By Brian Marson

Related Content

Pfizer Launches Expanded Access Program For CCR5 Antagonist Maraviroc

Dec 01 2006

FDA Seeking Input On Long-Term Follow-Up For HIV Entry Inhibitors

Nov 22 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window